ACM
CHRS icon

Antonetti Capital Management’s Coherus Oncology CHRS Stock Holding History

Antonetti Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$876 Buy
+234
New +$1.08K ﹤0.01% 293

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Antonetti Capital Management's CHRS Position: Q3 2023 in Review

Antonetti Capital Management opened a new position in Coherus Oncology (CHRS) in Q3 2023: 234 shares worth $876. The stake represents ﹤0.01% of the portfolio and ranks #293 among its holdings.

169 funds tracked by Wall St. Rank hold CHRS as of Q3 2023.

  • Antonetti Capital Management held 234 shares of Coherus Oncology worth $876 as of Q3 2023.
  • Coherus Oncology was a new Antonetti Capital Management position in Q3 2023.
  • Coherus Oncology made up ﹤0.01% of Antonetti Capital Management's portfolio in Q3 2023, its #293 holding.
  • 169 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2023.

Based on Antonetti Capital Management's 13F filing for Q3 2023, filed 9 Nov 2023.